Training in Anti-Cancer Drug Development

抗癌药物开发培训

基本信息

  • 批准号:
    8311779
  • 负责人:
  • 金额:
    $ 54.63万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1978
  • 资助国家:
    美国
  • 起止时间:
    1978-09-30 至 2014-06-30
  • 项目状态:
    已结题

项目摘要

This is an application requesting continued support for the Anti-Cancer Drug Development training grant, T32 CA09243, presently in its 30th year. The program is administered by the Department of Pharmacology & Molecular Sciences of the Johns Hopkins University, School of Medicine and its objective is to prepare pre- and postdoctoral students for research and teaching careers in the area of cancer-related drug development. *Predoctoral training provides highly qualified students with an integrated curriculum including course work and research. A reorganized and envigorated series of core courses in the basic sciences is taken during the first year and includes molecular biology and genomics, biochemical and biophysical principles, macromolecular structure and analysis, organic mechanisms in biology, cell structure and dynamics, pathways and regulation, and bioinformatics. Students receive additional instruction and exposure to pharmacology and oncology through a required graduate pharmacology course in the second year, and through elective courses, seminars, and journal clubs. Predoctoral trainees select a faculty preceptor and research project during their first two years, and devote most of their time after that to their thesis research and gaining experience with written and oral presentation of their work. Postdoctoral trainees devote most of their time to research carried out more independently, but with appropriate guidance from faculty mentors, for periods of one to three years. *The training program is interdisciplinary and brings together faculty from eight departments: Pharmacology & Molecular Sciences, Oncology, Biophysics & Biophysical Chemistry, Chemistry, Molecular Biology & Genetics, Cell Biology, Urology, and Environmental Health Sciences. Extensive faculty interaction is promoted by four new research Centers established by the Institute of Basic Biomedical Sciences and by common research interests. Extensive and productive student-faculty and student-student interactions are promoted by seminars, journal clubs, and by student- related activities such as recruiting weekends, research retreats, student-faculty dinners, and teaching, in addition to the laboratory research experience. *Since its beginning in 1979, this training program has supported over 130 pre-and postdoctoral trainees, most of whom have gone on to careers in science and many of whom have assumed leadership roles in the field of cancer research.
这是一份申请,请求继续支持抗癌药物开发培训赠款, T32 CA09243,目前已进入第30个年头。该计划由药理学系管理 和分子科学约翰霍普金斯大学医学院,其目标是准备 从事癌症相关药物研究和教学工作的博士后和博士后 发展。*博士前培训为高素质的学生提供综合课程,包括 课程作业和研究。重组和振兴一系列基础科学核心课程是 在第一年拍摄,包括分子生物学和基因组学,生化和生物物理 原理、大分子结构和分析、生物学中的有机机制、细胞结构和 动力学、途径和调控,以及生物信息学。学生接受额外的指导和 通过第二年必修的研究生药理学课程接触药理学和肿瘤学 每年,通过选修课、研讨会和杂志俱乐部。博士前实习生选择教师 在他们的头两年里,教授和研究项目,并在那之后的大部分时间致力于他们的 论文研究,并获得书面和口头报告的工作经验。博士后 受训者将大部分时间投入到研究中,这些研究更独立地进行,但有适当的指导 从教师导师那里,为期一到三年。*培训计划是跨学科的,并带来 来自药理学和分子科学、肿瘤学、生物物理学和 生物物理化学、化学、分子生物学和遗传学、细胞生物学、泌尿学和环境学 健康科学。由大学成立的四个新的研究中心促进了广泛的教师互动 基础生物医学科学研究所和共同的研究兴趣。广泛而富有成效 学生与教职员工和学生与学生之间的互动通过研讨会、期刊俱乐部和学生- 相关活动,如招聘周末、研究务虚会、师生聚餐和教学,在 除了实验室的研究经验。*自1979年开始以来,这一培训计划已经 支持了130多名博士后和博士后实习生,他们中的大多数都进入了科学和 他们中的许多人在癌症研究领域担任过领导角色。

项目成果

期刊论文数量(63)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
ERK phosphorylation is predictive of resistance to IGF-1R inhibition in small cell lung cancer.
  • DOI:
    10.1158/1535-7163.mct-12-0618
  • 发表时间:
    2013-06
  • 期刊:
  • 影响因子:
    5.7
  • 作者:
    Zinn RL;Gardner EE;Marchionni L;Murphy SC;Dobromilskaya I;Hann CL;Rudin CM
  • 通讯作者:
    Rudin CM
Direct protective effect of NAD(P)H:quinone reductase against menadione-induced chemiluminescence of postmitochondrial fractions of mouse liver.
NAD(P)H:醌还原酶对甲萘醌诱导的小鼠肝脏线粒体后部分化学发光的直接保护作用。
Novel induction by herpes simplex virus of hybrid interferon gene transcripts driven by the strong cytomegalovirus IE94 promoter.
单纯疱疹病毒由强巨细胞病毒 IE94 启动子驱动的杂合干扰素基因转录物的新诱导。
  • DOI:
    10.1128/jvi.61.3.819-828.1987
  • 发表时间:
    1987
  • 期刊:
  • 影响因子:
    5.4
  • 作者:
    Mosca,JD;Jeang,KT;Pitha,PM;Hayward,GS
  • 通讯作者:
    Hayward,GS
Identification of two lysosomal membrane glycoproteins.
  • DOI:
    10.1083/jcb.101.1.85
  • 发表时间:
    1985-07
  • 期刊:
  • 影响因子:
    7.8
  • 作者:
    CHEN, JW;MURPHY, TL;WILLINGHAM, MC;PASTAN, I;AUGUST, JT
  • 通讯作者:
    AUGUST, JT
Differential activation of hybrid genes containing herpes simplex virus immediate-early or delayed-early promoters after superinfection of stable DNA-transfected cell lines.
稳定 DNA 转染细胞系重复感染后,含有单纯疱疹病毒立即早期或延迟早期启动子的杂交基因的差异激活。
  • DOI:
    10.1128/jvi.56.3.867-878.1985
  • 发表时间:
    1985
  • 期刊:
  • 影响因子:
    5.4
  • 作者:
    Mosca,JD;Reyes,GR;Pitha,PM;Hayward,GS
  • 通讯作者:
    Hayward,GS
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JAMES T. STIVERS其他文献

JAMES T. STIVERS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JAMES T. STIVERS', 18)}}的其他基金

Discovery of Chemical Probes of SAMHD1 for Modulation of Cancer Therapy and the Immune System
发现用于调节癌症治疗和免疫系统的 SAMHD1 化学探针
  • 批准号:
    10163140
  • 财政年份:
    2020
  • 资助金额:
    $ 54.63万
  • 项目类别:
Discovery of Chemical Probes of SAMHD1 for Modulation of Cancer Therapy and the Immune System
发现用于调节癌症治疗和免疫系统的 SAMHD1 化学探针
  • 批准号:
    10396629
  • 财政年份:
    2020
  • 资助金额:
    $ 54.63万
  • 项目类别:
Discovery of Chemical Probes of SAMHD1 for Modulation of Cancer Therapy and the Immune System
发现用于调节癌症治疗和免疫系统的 SAMHD1 化学探针
  • 批准号:
    10650716
  • 财政年份:
    2020
  • 资助金额:
    $ 54.63万
  • 项目类别:
Fate of Invisible U/A Base Pairs Within HIV DNA in Myeloid Phagocytic Cells
骨髓吞噬细胞中 HIV DNA 中看不见的 U/A 碱基对的命运
  • 批准号:
    9138025
  • 财政年份:
    2016
  • 资助金额:
    $ 54.63万
  • 项目类别:
Persistence and Fate of Invisible U/A Pairs in HIV-1 Proviral DNA
HIV-1 前病毒 DNA 中隐形 U/A 对的持久性和命运
  • 批准号:
    8790165
  • 财政年份:
    2014
  • 资助金额:
    $ 54.63万
  • 项目类别:
Persistence and Fate of Invisible U/A Pairs in HIV-1 Proviral DNA
HIV-1 前病毒 DNA 中隐形 U/A 对的持久性和命运
  • 批准号:
    8910622
  • 财政年份:
    2014
  • 资助金额:
    $ 54.63万
  • 项目类别:
Purchase of a 600 MHz NMR Console and Probes
购买 600 MHz NMR 控制台和探头
  • 批准号:
    8051342
  • 财政年份:
    2011
  • 资助金额:
    $ 54.63万
  • 项目类别:
Fluorescence-Based Screen for Human DNA 5-Cytosine-methyltransferase 1
基于荧光的人类 DNA 5-胞嘧啶甲基转移酶 1 筛选
  • 批准号:
    8089372
  • 财政年份:
    2010
  • 资助金额:
    $ 54.63万
  • 项目类别:
Fluorescence-Based Screen for Human DNA 5-Cytosine-methyltransferase 1
基于荧光的人类 DNA 5-胞嘧啶甲基转移酶 1 筛选
  • 批准号:
    8010339
  • 财政年份:
    2010
  • 资助金额:
    $ 54.63万
  • 项目类别:
High Throughput Assay:Topoisomerase Enzyme Targets (RMI)
高通量检测:拓扑异构酶靶标 (RMI)
  • 批准号:
    7022489
  • 财政年份:
    2005
  • 资助金额:
    $ 54.63万
  • 项目类别:

相似海外基金

Development of CRC Training Program to Improve the International Competitiveness in Drug Development
开展CRC培训项目,提高药物研发国际竞争力
  • 批准号:
    26670272
  • 财政年份:
    2014
  • 资助金额:
    $ 54.63万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
CIHR Multidisciplinary Training in Drug Development (M-TraDD) Program
CIHR 药物开发多学科培训 (M-TraDD) 计划
  • 批准号:
    176839
  • 财政年份:
    2008
  • 资助金额:
    $ 54.63万
  • 项目类别:
    Operating Grants
CIHR Drug Development Training Program (DDTP)
CIHR 药物开发培训计划 (DDTP)
  • 批准号:
    176742
  • 财政年份:
    2008
  • 资助金额:
    $ 54.63万
  • 项目类别:
    Operating Grants
UCSD Cancer Center Training Program in Drug Development
加州大学圣地亚哥分校癌症中心药物开发培训项目
  • 批准号:
    8335427
  • 财政年份:
    2006
  • 资助金额:
    $ 54.63万
  • 项目类别:
UCSD Cancer Center Training Program in Drug Development
加州大学圣地亚哥分校癌症中心药物开发培训项目
  • 批准号:
    7446128
  • 财政年份:
    2006
  • 资助金额:
    $ 54.63万
  • 项目类别:
UCSD Cancer Center Training Program in Drug Development
加州大学圣地亚哥分校癌症中心药物开发培训项目
  • 批准号:
    9308867
  • 财政年份:
    2006
  • 资助金额:
    $ 54.63万
  • 项目类别:
UCSD Cancer Center Training Program in Drug Development
加州大学圣地亚哥分校癌症中心药物开发培训项目
  • 批准号:
    7885313
  • 财政年份:
    2006
  • 资助金额:
    $ 54.63万
  • 项目类别:
UCSD Cancer Center Training Program in Drug Development
加州大学圣地亚哥分校癌症中心药物开发培训项目
  • 批准号:
    8517025
  • 财政年份:
    2006
  • 资助金额:
    $ 54.63万
  • 项目类别:
UCSD Cancer Center Training Program in Drug Development
加州大学圣地亚哥分校癌症中心药物开发培训项目
  • 批准号:
    7123230
  • 财政年份:
    2006
  • 资助金额:
    $ 54.63万
  • 项目类别:
UCSD Cancer Center Training Program in Drug Development
加州大学圣地亚哥分校癌症中心药物开发培训项目
  • 批准号:
    8680016
  • 财政年份:
    2006
  • 资助金额:
    $ 54.63万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了